Education
About Us
Working with TipRanks
Follow Us
Xenon Pharmaceuticals (XENE)
:XENE
XENE Stock Chart & Stats
Day’s Range― - ―
52-Week Range$26.74 - $46.00
Previous CloseN/A
Volume41.45K
Average Volume (3M)755.70K
Market Cap
$2.88B
Enterprise Value$2.45B
Total Cash (Recent Filing)$60.16M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta1.09
Next Earnings
May 13, 2025EPS Estimate
-0.91Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-3.01
Shares Outstanding76,542,810
10 Day Avg. Volume814,336
30 Day Avg. Volume755,699
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-12.40
P/FCF Ratio0.00
Enterprise Value/Market Cap0.85
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda-8.87
Forecast
1Y Price Target
$55.00Price Target Upside46.20% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering13
---
Xenon News
PremiumCompany Announcements
Xenon Pharmaceuticals to Present Promising Azetukalner Data at AAN 2025
PremiumCompany Announcements
Xenon Pharmaceuticals to Present at Stifel 2025 Virtual CNS Forum
PremiumCompany Announcements
Xenon Pharmaceuticals’ Earnings Call Highlights Progress and Challenges
---
Bulls Say, Bears Say
Bulls Say
Financial PerformanceXenon ended the quarter with $754 million in cash, which management believes should fund operations into 2027.
Research And DevelopmentThe company is expanding its psychiatry program, indicating growth and diversification in its business strategy.
Stock ValuationXENE stock looks cheap heading into two datasets with oral azetukalner, which could lead to significant stock moves.
Bears Say
Leadership ChangesXENE shares are under pressure most likely due to news of the CFO departing.
Price Target AdjustmentThe increase in research and development spending, along with other expenses, has led to a reduction in the price target for Xenon Pharmaceuticals from $55 to $50.
---
Ownership Overview
0.13% Insiders
28.60% Mutual Funds
0.44% Other Institutional Investors
68.98% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
XENE FAQ
What was Xenon Pharmaceuticals’s price range in the past 12 months?
Xenon Pharmaceuticals lowest stock price was $26.74 and its highest was $46.00 in the past 12 months.
What is Xenon Pharmaceuticals’s market cap?
Xenon Pharmaceuticals’s market cap is $2.88B.
When is Xenon Pharmaceuticals’s upcoming earnings report date?
Xenon Pharmaceuticals’s upcoming earnings report date is May 13, 2025 which is in 16 days.
How were Xenon Pharmaceuticals’s earnings last quarter?
Xenon Pharmaceuticals released its earnings results on Feb 27, 2025. The company reported -$0.84 earnings per share for the quarter, beating the consensus estimate of -$0.861 by $0.021.
Is Xenon Pharmaceuticals overvalued?
According to Wall Street analysts Xenon Pharmaceuticals’s price is currently Undervalued.
Does Xenon Pharmaceuticals pay dividends?
Xenon Pharmaceuticals does not currently pay dividends.
What is Xenon Pharmaceuticals’s EPS estimate?
Xenon Pharmaceuticals’s EPS estimate is -0.91.
How many shares outstanding does Xenon Pharmaceuticals have?
Xenon Pharmaceuticals has 76,542,810 shares outstanding.
What happened to Xenon Pharmaceuticals’s price movement after its last earnings report?
Xenon Pharmaceuticals reported an EPS of -$0.84 in its last earnings report, beating expectations of -$0.861. Following the earnings report the stock price went down -3.367%.
Which hedge fund is a major shareholder of Xenon Pharmaceuticals?
Currently, no hedge funds are holding shares in XENE
---
Xenon Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$55.00 (46.20% Upside)
$55.00 (46.20% Upside)
Blogger Sentiment
Bullish
XENE Sentiment 70%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Decreased
By 234.8K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $770.9K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Positive
Last 7 Days ▼ 1.2%
Last 30 Days ▼ 3.8%
Last 30 Days ▼ 3.8%
News Sentiment
Neutral
Bullish news 50%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-6.18%
12-Months-Change
Fundamentals
Return on Equity
-27.85%
Trailing 12-Months
Asset Growth
10.60%
Trailing 12-Months
Company Description
Xenon Pharmaceuticals
Xenon Pharmaceuticals Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics to treat patients with neurological disorders in Canada. Its clinical development pipeline includes XEN496, A Kv7 potassium channel opener that is Phase III clinical trials for the treatment of KCNQ2 developmental and epilepsy encephalopathy; and XEN1101, A Kv7 potassium channel opener, which is in Phase II clinical trial for the treatment of epilepsy and other neurological disorders. The company's product candidates also comprise NBI-921352, a selective Nav1.6 sodium channel inhibitor that is in Phase II clinical trials for the treatment of SCN8A developmental and epileptic encephalopathy, and other potential indications, including adult focal epilepsy; and XEN007, A central nervous system-acting calcium channel modulator, which is in Phase II clinical trials. It has a license and collaboration agreement with the Neurocrine Biosciences, Inc. to develop treatments for epilepsy; and with Flexion Therapeutics, Inc. to develop PCRX301 (XEN402, a Nav1.7 inhibitor) for the treatment of post-operative pain. Xenon Pharmaceuticals Inc. was incorporated in 1996 and is headquartered in Burnaby, Canada.
---
XENE Earnings Call
Q4 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call reflected a positive sentiment overall. Xenon Pharmaceuticals demonstrated significant progress in its clinical development programs, including plans to expand azetukalner into new indications such as bipolar depression. The company is also in a strong financial position to support its pipeline and strategic goals. However, challenges in enrolling patients for the PGTC study and the announced departure of CFO Sherry Aulin were noted.Read More>---
XENE Stock 12 Month Forecast
Average Price Target
$55.00
▲(46.20% Upside)
Technical Analysis
Merus
―
Apellis Pharmaceuticals
―
Scholar Rock Holding
―
Immunovant
―
MoonLake Immunotherapeutics
―
Best Analysts Covering XENE
1 Year
1 Year Success Rate
11/14 ratings generated profit
1 Year Average Return
+31.62%
reiterated a buy rating 12 days ago
Copying Andrew Tsai's trades and holding each position for 1 Year would result in 78.57% of your transactions generating a profit, with an average return of +31.62% per trade.
---